Epigenetic Mechanisms in Respiratory Muscle Dysfunction of Patients with Chronic Obstructive Pulmonary Disease

Ester Puig-Vilanova1,2, Rafael Aguiló3, Alberto Rodríguez-Fuster3, Juana Martínez-Llorens1,2, Joaquim Gea1,2, Esther Barreiro1,2*

1 Pulmonology Department-Muscle and Respiratory System Research Unit (URMAR), IMIM-Hospital del Mar, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Barcelona Biomedical Research Park (PRBB), Barcelona, Spain, 2 Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain, 3 Thoracic Surgery Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain

Abstract

Epigenetic events are differentially expressed in the lungs and airways of patients with chronic obstructive pulmonary disease (COPD). Moreover, epigenetic mechanisms are involved in the skeletal (peripheral) muscle dysfunction of COPD patients. Whether epigenetic events may also regulate respiratory muscle dysfunction in COPD remains unknown. We hypothesized that epigenetic mechanisms would be differentially expressed in the main inspiratory muscle (diaphragm) of patients with COPD of a wide range of disease severity compared to healthy controls. In diaphragm muscle specimens (thoracotomy due to lung localized neoplasms) of sedentary patients with mild-to-moderate and severe COPD, with preserved body composition, and sedentary healthy controls, expression of muscle-enriched microRNAs, histone acetyltransferases (HATs) and deacetylases (HDACs), total DNA methylation and protein acetylation, small ubiquitin-related modifier (SUMO) ligases, muscle-specific transcription factors, and muscle structure were explored. All subjects were also clinically evaluated: lung and muscle functions and exercise capacity. Compared to healthy controls, patients exhibited moderate airflow limitation and diffusion capacity, and reduced exercise tolerance and transdiaphragmatic strength. Moreover, in the diaphragm of the COPD patients, muscle-specific microRNA expression was downregulated, while HDAC4 and myocyte enhancer factor (MEF)2C protein levels were higher, and DNA methylation levels, muscle fiber types and sizes did not differ between patients and controls. In the main respiratory muscle of COPD patients with a wide range of disease severity and normal body composition, muscle-specific microRNAs were downregulated, while HDAC4 and MEF2C levels were upregulated. It is likely that these epigenetic events act as biological adaptive mechanisms to better overcome the continuous inspiratory loads of the respiratory system in COPD. These findings may offer novel therapeutic strategies to specifically target respiratory muscle dysfunction in patients with COPD.

Citation: Puig-Vilanova E, Aguiló R, Rodríguez-Fuster A, Martínez-Llorens J, Gea J, et al. (2014) Epigenetic Mechanisms in Respiratory Muscle Dysfunction of Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE 9(11): e111514. doi:10.1371/journal.pone.0111514

Editor: Marco Idzko, University Hospital Freiburg, Germany

Received May 2, 2014; Accepted September 26, 2014; Published November 4, 2014

Copyright: © 2014 Puig-Vilanova et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

Funding: This study has been supported by CIBERES; FIS 11/02029; FIS 12/02534; SAF-2011-26908; 2009-SGR-393; SEPAR 2009; FUCAP 2011; FUCAP 2012; and Marató TV3 (MTV3-07-1010) (Spain). Dr. Esther Barreiro was a recipient of the ERS COPD Research Award 2008. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: ebarreiro@imim.es

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is currently a major leading cause of mortality worldwide. In COPD patients, muscle dysfunction is a frequent comorbidity that imposes a substantial impact on their exercise tolerance and quality of life [1,2]. Despite that limb muscles are usually more severely affected than the ventilatory muscles in these patients, evidence shows that respiratory muscle dysfunction also contributes to poor exercise tolerance [3]. Indeed, it has been shown that respiratory muscle dysfunction may contribute to hypercapnic respiratory failure, exercise limitation, increased risk for acute exacerbations, and eventual death in patients with COPD [4]. Several pathophysiological factors and biological mechanisms contribute to COPD muscle dysfunction. Specifically, the increased inspiratory loads imposed by the airflow limitation and the modifications observed in thorax geometry that cause diaphragm length shortening are the main contributing factors to respiratory muscle dysfunction in COPD [3]. However, as a result of the continuous inspiratory loads overcome by the patients, the main inspiratory muscle, the diaphragm, has also been shown to experience a training-like effect, characterized by a more fatigue-resistant phenotype when compared to healthy subjects [3,5]. Other factors such as cigarette smoke, hypoxia, hypercapnia and acidosis, exacerbations, nutritional abnormalities, and sarcopenia (aging) may also be involved in the etiology of COPD respiratory muscle dysfunction [3]. Furthermore, biological mechanisms [3] such as structural abnormalities [6], muscle remodeling [7], oxidative stress [8], and metabolic derangements [9] have also been shown to mediate respiratory muscle dysfunction.
dysfunction in COPD. Recently, epigenetic events, defined as the heritable mechanisms that do not affect DNA sequence, have also emerged as potentially involved in the etiology of muscle dysfunction of the lower limbs in COPD patients [10–12], and in experimental models of disuse [13,14] and hypertrophy [15].

Specifically, the expression of noncoding single-stranded RNA molecules, microRNAs (miRNAs) specific to skeletal muscles, was downregulated in limb muscles and blood of patients with severe COPD [10,11]. DNA methylation is a biochemical process characterized by the addition of a methyl group to the 5 position of the cytosine that stands before a guanine molecule in the same chain. DNA methylation is the most stable modification of chromatin that may vary during development and aging in cells. Moreover, histone acetylation, defined as the balance between histone acetyltransferases (HATs) and histone deacetylases (HDACs) also seemed to regulate muscle plasticity in response to environmental factors in several models [16,17]. Moreover, plasma levels of muscle-specific miRNAs were also shown to be increased in patients with severe COPD and peripheral muscle dysfunction [10]. Nonetheless, it remains to be identified whether differences in the activity of the muscles may influence the expression of epigenetic events. In this regard, elucidation of the epigenetic profile of the diaphragm muscle in patients with COPD has not been so far documented.

Interestingly, accumulation of small ubiquitin-related modifier (SUMO) ligases has been shown to underlie muscular dystrophies and to favor sarcopenia and muscle wasting through premature senescence of satellite cells in experimental models [18]. It remains unknown to identify whether this mechanism could also be involved in the etiology of respiratory muscle dysfunction in COPD.

On this basis, we hypothesized that epigenetic mechanisms would be differentially expressed in the main inspiratory muscle of patients with COPD of a wide range of disease severity compared to healthy controls. Accordingly, our primary objectives were to assess in the diaphragms of patients with COPD, the expression of a wide number of epigenetic mechanisms including muscle-enriched miRNAs, as well as the expression of SUMO-2/3. The existence of potential correlations between the different study variables was also analyzed in the patients. Diaphragm specimens were also obtained in healthy controls for the purpose of the investigation, and both patients and control individuals were clinically and functionally evaluated.

Methods

(See the File S1 for detailed information on all the study methodologies).

Study subjects

Eighteen patients with stable COPD [19–21] [mild (n = 9), moderate (n = 6) and severe (n = 3)] with normal body composition and 10 age-matched sedentary controls were recruited on an outpatient basis. Diaphragm muscle specimens were obtained from all subjects who underwent thoracotomy for a localized lung neoplasm.

The current investigation was designed in accordance with both the ethical standards on human experimentation in our institutions and the World Medical Association guidelines (Helsinki Declaration of 2008) for research on human beings. Approval was obtained from the institutional Ethics Committees on Human Investigation (Hospital del Mar, Barcelona). Informed written consent was obtained from all individuals.

Anthropometrical and Functional Assessment

Anthropometrical, lung and muscle function evaluations were conducted as previously described [22].

Muscle biopsies and blood samples

Diaphragm biopsies. During thoracotomy for localized lung lesions, diaphragm biopsy specimens were obtained from the anterior costal diaphragm lateral to the insertion of the phrenic nerve [23].

Blood samples were drawn at 8:00h am after an overnight fasting period in both patients and healthy controls.

Molecular biology analyses

DNA isolation. Total DNA was isolated from vastus lateralis muscle of all study subjects using QIAamp DNA Mini Kit (Qiagen, Redwood City, CA, USA) [12,24], following the manufacturer's protocol of DNA purification from tissues, and without the use of RNase A. Total DNA obtained from muscles was quantified using a spectrophotometer (NanoDrop, Thermo Scientific, Wilmington, DE, USA).

Quantification of Methylated DNA using enzyme-linked immunosorbent assay (ELISA)-based immunoassay. Global 5-methylcytosine (5-mC) in DNA was quantified in the vastus lateralis of both patients and healthy controls using MethylFlash Methylated DNA Quantification Colorimetric Kit (Epigentek, Farmingdale, NY, USA) following the precise manufacturer's instructions and previous studies [12,25]. The minimum detectable concentration of methylated DNA in the samples was set to be 0.2 ng of methylated DNA. Data are expressed as the percentage of total methylated DNA to total DNA in the muscle samples.

RNA isolation. Total RNA was first isolated from snap-frozen skeletal muscles using Trizol reagent following the manufacturer’s protocol (Life technologies, Carlsbad, CA, USA).

MicroRNA and mRNA reverse transcription (RT). MicroRNA RT was performed using TaqMan microRNA assays (Life Technologies) following the manufacturer’s instructions.

Real-time-PCR amplification (qRT-PCR). TaqMan based qPCR reactions were performed using the ABI PRISM 7900HT Sequence Detector System (Applied BioSystems, Foster City, CA, USA) together with a commercially available predesigned microRNA assay, primers, and probes as shown in Tables 1 and 2 [26]. Results in the figures are expressed as the expression of fold change relative to mean value of the control group, which was equal to 1.

Immunoblotting of 1D electrophoresis. Protein levels of the different molecular markers analyzed in the study were explored by means of immunoblotting procedures as previously described [12,22,23] (Figure S1 in file S1).

Muscle fiber counts and morphometry. On 3-micrometer muscle paraffin-embedded sections from diaphragms of the study groups, MyHC-I and –II isoforms were identified using specific antibodies as published elsewhere [22,23].

Statistical Analysis

Data are expressed as mean (standard deviation). Comparisons of physiological, clinical, molecular, and structural variables between the two study groups (COPD patients and control subjects) were analyzed using the Student’s t-test. Among the patients, potential correlations between clinical, physiological and biological variables were explored using the Pearson’s correlation coefficient.
Results

Clinical characteristics

Table 3 illustrates all clinical and functional variables of controls and COPD patients recruited in the investigation. Age, BMI, and FFMI did not significantly differ among the study subjects. COPD patients exhibited a wide range of airflow limitation from mild-to-moderate to severe disease and functional signs of emphysema compared to control subjects. Exercise capacity as measured by six-minute walking distance and cycloergometry and muscle strength as measured by maximal transdiaphragmatic pressure (Pdimax) and quadriceps isometric maximum voluntary contraction (QMVC) were decreased in all groups of COPD patients compared to healthy controls. Levels of fibrinogen, C-reactive protein, and globular sedimentation velocity were higher in the blood of the patients compared to control subjects.

Muscle biological markers

DNA methylation. In the diaphragm, the percentage of methylated DNA to total DNA did not differ between patients and control subjects (Figure 1).

MicroRNAs. Compared to healthy controls, expression levels of miR-1, -133a, and -206 were significantly downregulated in the diaphragm of the patients (Figures 2A–2C), while levels of miR-486, -27a, -29b, and -181a did not differ between the study groups (Figures 2D and 3A–3C).

Histone modifications. In the respiratory muscle, levels of total lysine-acetylated proteins and mRNA expression levels of HAT p300 did not significantly differ between patients and controls (Figures 4A and 4B, respectively). Compared to controls, protein levels of HDAC4 were increased in the diaphragm of the patients (Figure 5C), while no differences were observed in protein levels of HDAC3, HDAC6, and SIRT1 (Figures 5A, 5B, and 5D, respectively).

Myogenic transcription factors. Compared to controls, protein levels of MEF2C were increased in the diaphragm of the COPD patients (Figure 6A), whereas protein levels of myocyte-enhancer factor (MEF2D, YY1, MyoD, Pax7, serum response factor (SRF) and BRG1/BRM-associated factor (BAF60c did not differ between the study groups (Figures 6B–6D and 7A–7D).

Expression of SUMO. mRNA expression levels of SUMO2 and SUMO3 did not differ between patients and controls in the diaphragm muscle (Figures 8A–8B respectively).

Muscle structure

Fiber type composition. In the respiratory muscle, no significant differences were observed in either fiber type proportions or sizes between patients and controls (Table 4 and Figure S2 in File S1). In the diaphragm of all COPD patients, an inverse correlation was found between proportions of type I fibers and FEV1 (r = -0.493, p = 0.038).

| Gene Symbol | Assay ID | Taqman probe context sequence (5’-3’) | Genbank accession number |
|-------------|---------|-------------------------------------|--------------------------|
| EP300       | Hs00914223_m1 | CACCATGGAAGAGCATAAAGGGTGC | NM_001429.3 |
| SUMO2       | Hs02743873_g1 | CATTGTAAAACCAAGGACATTTTA | NM_006937.3 |
| SUMO3       | Hs00739248_m1 | GCGAGAGGCCAGGCTCAGCAGGAG | NM_006936.2 |
| GAPDH       | Hs00999905_m1 | GAGGCGGCTGCTACAGAGGCGTGT | NM_002046.4 |

Abbreviations: ID, identification; Hs, homo sapiens; m1, multi-exonic gene assay does not detect genomic DNA; NM, mRNA RefSeq database category; SUMO, small ubiquitin-like modifier; g1, multi-exonic gene assay may detect genomic DNA if present in the sample; and GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

doi:10.1371/journal.pone.0111514.t002
Discussion

The main findings in the current study were that in the diaphragm of patients with COPD of a wide range of airway obstruction and normal body composition compared to healthy controls, the expression of muscle-specific microRNAs such as miR-1, miR-133, and miR-206 was downregulated, while levels of miR-486, miR-27a, miR-29b, and miR-181a did not differ between the study subjects. Moreover, protein levels of HDAC4 and MEF2C were greater in the respiratory muscles of the patients than in the controls. No significant differences were observed in total protein acetylation and HAT levels, in the content of several muscle-specific transcription factors, or SUMOylation expression in the diaphragm between patients and control subjects (Figure 9).

Table 3. Anthropometric characteristics and functional status of all the subjects undergoing thoracotomy.

|                           | Controls | Mild, moderate, and severe COPD |
|---------------------------|----------|----------------------------------|
|                           | N = 10   | N = 18 (9, 6, and 3 patients)    |
| **Anthropometry**         |          |                                  |
| Age (years)               | 67 (5)   | 69 (7)                           |
| BMI (kg/m²)               | 25 (3)   | 26 (3)                           |
| FFMI (kg/m²)              | 18 (1)   | 18 (1)                           |
| **Smoking History**       |          |                                  |
| Active, N, %              | 4, 40    | 10, 56                           |
| Ex-smoker, N, %           | 5, 50    | 8, 44                            |
| Never smoker, N, %        | 1, 10    | 0, 0                             |
| Pack/year                 | 46 (13)  | 59 (30)                          |
| **Lung function**         |          |                                  |
| FEV₁ (% pred)             | 81 (8)   | 62 (15) ***                      |
| FVC (% pred)              | 80 (5)   | 80 (14)                          |
| FEV₁/FVC (%)              | 70 (5)   | 57 (8) ***                       |
| RV (% pred)               | 92 (17)  | 143 (40) ***                     |
| TLC (% pred)              | 98 (18)  | 101 (15)                         |
| RV/TLC                    | 46 (6)   | 51 (10)                          |
| DLco (% pred)             | 90 (16)  | 69 (12) **                       |
| KCO (% pred)              | 93 (11)  | 69 (17) ***                      |
| PaO₂ (kPa)                | 11 (2)   | 10 (1)                           |
| PaCO₂ (kPa)               | 5.5 (0.6)| 5.3 (0.8)                        |
| **Exercise capacity**     |          |                                  |
| VO₂ peak (% pred)         | 84 (10)  | 64 (19) ***                      |
| WR peak (% pred)          | 63 (5)   | 46 (13) ***                      |
| Six-min walking test (m)  | 511 (69) | 425 (101) *                      |
| **Muscle function**       |          |                                  |
| MIP (cm H₂O)              | 87 (4)   | 82 (17)                          |
| Pdi max (cm H₂O)          | 134 (21) | 102 (14) ***                     |
| QMVC (kg)                 | 37 (1)   | 34 (3) ***                       |
| **Blood parameters**      |          |                                  |
| Albumin (g/dL)            | 4.1 (0.4)| 4.0 (0.4)                        |
| Total proteins (g/dL)     | 7.1 (0.9)| 6.7 (0.6)                        |
| CRP (mg/dL)               | 0.3 (0.2)| 0.6 (0.4) *                      |
| Fibrinogen (mg/dL)        | 316 (23) | 470 (178) **                     |
| GSV (mm/h)                | 6.8 (3.5)| 15 (9.5) **                      |

Values are expressed as mean (standard deviation).
Abbreviations: COPD, chronic obstructive pulmonary disease; N, number of patients; m, meters; BMI, body mass index; FFMI, fat-free mass index; kg, kilograms; FEV₁, forced expiratory volume in one second; pred, predicted; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; DLco, carbon monoxide transfer; KCO, Krough transfer factor; PaO₂, arterial oxygen partial pressure; PaCO₂, arterial carbon dioxide partial pressure; VO₂ peak, peak exercise oxygen uptake; WR peak, peak work rate; min, minute; MIP, maximal inspiratory pressure; cm, centimeters; H₂O, water; Pdi max, maximal transdiaphragmatic pressure; QMVC, quadriceps maximal velocity contraction; g, grams; dl, deciliter; mg, milligrams; CRP, C-reactive protein; GSV, globular sedimentation velocity; mm, millimeters; h, hour.
Statistical significance: *, p<0.05, **, p<0.01, ***, p<0.001 between COPD patients and control subjects.
doi:10.1371/journal.pone.0111514.t003
decrease in diaphragm force as measured by transdiaphragmatic pressure. As far as we are concerned, the present study is the first to have characterized the epigenetic profile of the main respiratory muscle of patients with COPD.

Respiratory muscle dysfunction and structure in the COPD patients

In the present investigation, as also shown in former studies [23,27], patients undergoing thoracotomy exhibited mild-to-moderate and severe COPD together with a moderate decrease
in their exercise performance and in both respiratory and limb muscle strengths. Additionally, as also previously reported [28,29], signs of chronic disease were evidenced by the significant rise in levels of general inflammatory parameters observed in the COPD patients. Importantly, despite that total respiratory muscle force was not reduced in the patients, the specific assessment of

![Figure 3. Levels of expression of muscle-enriched microRNAs in the diaphragms of COPD patients and healthy controls.](image)

**A**

[Graph showing mean values and standard deviation (relative expression) of miR-27a, -29b, and -181a expression in COPD patients compared to controls (panels A, B, and C). Samples were always run in triplicates and their corresponding expression was calculated as the mean value of the 3 measurements.]

**B**

[Graph showing mean values and standard deviation (relative expression) of miR-27a, -29b, and -181a expression in COPD patients compared to controls (panels A, B, and C). Samples were always run in triplicates and their corresponding expression was calculated as the mean value of the 3 measurements.]

**C**

[Graph showing mean values and standard deviation (relative expression) of miR-27a, -29b, and -181a expression in COPD patients compared to controls (panels A, B, and C). Samples were always run in triplicates and their corresponding expression was calculated as the mean value of the 3 measurements.]

Figure 3. Levels of expression of muscle-enriched microRNAs in the diaphragms of COPD patients and healthy controls. Mean values and standard deviation (relative expression) of miR-27a, -29b, and -181a expression did not differ (n.s., non-significant) in the diaphragms of COPD patients compared to controls (panels A, B, and C). Samples were always run in triplicates and their corresponding expression was calculated as the mean value of the 3 measurements.

doi:10.1371/journal.pone.0111514.g003

![Figure 4. Protein levels of total acetyl-lysine protein content and mRNA levels of the HAT p300 in the diaphragms of COPD patients and controls.](image)

**A**

[Graph showing mean values and standard deviation (protein levels) of total lysine-acetylated proteins in COPD patients compared to controls (panels A and B).]

**B**

[Graph showing mean values and standard deviation (protein levels) of total lysine-acetylated proteins in COPD patients compared to controls (panels A and B).]

Figure 4. Protein levels of total acetyl-lysine protein content and mRNA levels of the HAT p300 in the diaphragms of COPD patients and controls. Mean values and standard deviation (protein levels) of total lysine-acetylated proteins and (relative expression) of nuclear cofactor p300 expression did not differ (n.s., non-significant) in the diaphragms of COPD patients compared to controls (panels A and B).

doi:10.1371/journal.pone.0111514.g004
Diaphragm strength showed a significant reduction of this parameter in that group compared to values detected in the control subjects. The degree of diaphragm muscle dysfunction seen in the patients may not be sufficiently relevant to induce a significant clinical impact at rest, but it could certainly have implications during exercise and exacerbations. In line with these findings, proportions and sizes of the diaphragm muscle fibers did not differ between patients and control subjects in the study. It is likely that changes taking place in muscle structure towards a more fatigue-resistant phenotype require a more drastic loss in muscle strength of the diaphragm, which is, in turn, directly related to the degree of the airway obstruction. In the present study, most of the patients exhibited mild and moderate airflow limitation, while only three patients had severe COPD. In previous studies from our group [23,27] and others [7,30,31], respiratory muscle strength and diaphragm force parameters were more significantly reduced than in the current investigation as COPD patients were more severe. Moreover, in those investigations [7,23,27,30,31] a fiber-type switch towards a more resistant phenotype was also observed in the diaphragm of the severe COPD patients. In fact, in the study, the negative correlation encountered between the degrees of the airway obstruction as measured by FEV₁ and the proportions of the slow-switch fibers in the diaphragm further support these conclusions.

Epigenetic events in the diaphragm muscle of COPD patients

Importantly, expression of the muscle-specific microRNAs miR-1, -133, and -206 was downregulated in the diaphragm of patients with mild-to-moderate and severe COPD, whereas the expression of miR-486, -27a, -29b, and -181a did not differ between patients and controls. In COPD, the inspiratory loads to which the respiratory muscle is continuously exposed may be a major player accounting for this specific pattern of microRNA expression. Aside from the classic transcription factors, muscle-specific microRNAs play a relevant role in the regulation of muscle development and repair after injury by targeting different pathways [11,32,33]. While miR-1 and -206 promote cell differentiation and innervation [11,32–34], miR-206 induces myoblast proliferation by inhibiting myotube formation [11,32,33]. Recently, genetic deletion of miR-206 was also shown to delay regeneration of skeletal muscles in mice exposed to cardiotoxin injury and their myofibers were of smaller size compared to the wild type controls [35]. On this basis, it is likely that the downregulation of the muscle-specific microRNAs, especially that of miR-206 may have prevented changes in the phenotype of the diaphragm fibers in the patients, since it seems to be deeply involved in this biological process [35]. Moreover, as diaphragm muscle injury was demonstrated to be directly related to the degree of the airway obstruction, it is likely that the downregulation of these microRNAs may have contributed to the development of muscle dysfunction in patients with COPD.
obstruction and pulmonary hyperinflation in COPD [36], it could also be argued that levels of injury within the respiratory muscle fibers of the patients in this study may have been rather low to trigger miR-206 expression.

In line with the findings reported in the current study, the expression of miR-1 and -133 was also downregulated in response to muscle overload in an experimental model of hypertrophy [15]. A likely explanation to account for all these results is that the decreased expression of miR-1 and -133 may promote adaptation to overload by eliminating the posttranscriptional repression of genes and pathways involved in muscle growth such as insulin-like growth factor (IGF)-1 and SRF. In fact, protein levels of the transcription factors SRF, myoD, Pax7, and BAF60 did not differ between patients and control subjects in the study. It would be possible to conclude that the downregulation of muscle-specific microRNAs, which are part of one of the most ancient microRNA clusters, may play a crucial role in adaptation to overload in the diaphragm muscle of patients with moderate COPD.

In keeping with the findings observed in the study, spaceflight and hindlimb suspension models of atrophy also resulted in a downregulation of muscle-enriched microRNAs in the limb muscles of the exposed rodents [13,14]. Furthermore, a pioneering study conducted on limb muscles of severe COPD and relatively preserved body composition also showed a downregulation of miR-1 among the analyzed microRNAs [11]. Furthermore, miR-1 and -499 expression levels were also positively associated with FFMI and proportions of type I fibers among the severe patients in that study [11]. Taken together, all these findings may imply the existence of a rather complex epigenetic regulation of muscle function in COPD patients than a simple up or downregulation of genes and pathways involved in muscle repair and myogenesis.

Hyperacetylation of proteins may participate in the process of muscle wasting through several mechanisms that enhance protein catabolism by ubiquitin-ligase activity of several HATs, and by dissociation of proteins from cellular chaperones [37]. Among several HATs, the nuclear cofactor p300 has been shown to regulate muscle differentiation and loss in several experimental in vivo and in vitro models [16,38]. In the current investigation, no differences were found in p300 expression levels in the diaphragm muscle of patients with moderate COPD. Differences in the study models may account for such discrepancies. Protein acetylation also relies on histone deacetylase activity. For instance, in COPD patients HDAC activity was demonstrated to be reduced in the lungs and airways of COPD patients [39]. Furthermore, in an experimental model, treatment of normal rats with the HDAC inhibitor trichostatin A also caused emphysema in the lungs of the rodents through the induction of several biological mechanisms (apoptosis

Figure 6. Protein levels of transcription factors shown to be involved in myogenesis and muscle repair in the diaphragms of COPD patients and controls. Mean values and standard deviation (protein levels) of MEF2C were significantly increased (*: p<0.05) in the diaphragms of COPD patients compared to controls (panel A). Nevertheless, mean values and standard deviation (protein levels) of MEF2D and YY1 expression did not differ (n.s., non-significant) between the study subjects (n.s., non-significant, panels B and C, respectively).

doi:10.1371/journal.pone.0111514.g006
and suppression of vascular remodeling) that may contribute to the perpetuation of the lung destruction [40].

In the present study, protein levels of HDAC3, HDAC6, and SIRT-1 in the respiratory did not show any significant difference between patients and controls. Nonetheless, a significant increase in HDAC4 levels was detected in the diaphragm of the patients compared to control subjects. These results are in agreement with those previously reported [11] in the vastus lateralis of patients.

Figure 7. Protein levels of transcription factors shown to be involved in myogenesis and muscle repair in the diaphragms of COPD patients and controls. Mean values and standard deviation (protein levels) of MyoD, Pax7, SRF, and BAF60c expression did not differ (n.s., non-significant) between the study subjects (n.s., non-significant, panels A, B, C, and D, respectively).

doi:10.1371/journal.pone.0111514.g007

Figure 8. mRNA expression of SUMO-2 and SUMO-3 in the diaphragms of COPD patients and controls. Mean values and standard deviation (relative expression) of SUMO-2 and SUMO-3 expression did not differ (n.s., non-significant, panels A and B) in the diaphragms of COPD patients compared to controls. Samples were always run in triplicates and their corresponding expression was calculated as the mean value of the 3 measurements.

doi:10.1371/journal.pone.0111514.g008
with severe COPD and preserved body composition. Indeed, the interaction between miR-1 and HDAC4 was suggested to contribute to muscle mass maintenance, probably through insulin-like growth factor (IGF)-1 signaling [11,41]. It should be noted that while HDAC activity and expression are downregulated in the lungs of emphysema models [39,40], HDAC4 protein levels were increased in the diaphragm of the same type of patients. Clearly, the function or the organ and type of tissue seem to strongly account for differences in the levels and pattern of expression of the different HDACs. Importantly, the findings reported herein are also in accordance with those reported in a very recent investigation [42], in which upregulation of miR-1, miR-133, and miR-206 was induced by HDAC inhibition in a murine model of muscle regeneration. In view of those findings [42] and results shown in the present study, it could be argued that HDAC activity is required for the upregulation of muscle-specific microRNAs expression in models of muscle injury.

Although DNA methylation plays a role in cell fate and development, no significant differences were observed in the expression of this epigenetic marker in the diaphragm of the patients compared to the healthy controls. In light of the findings seen in the COPD patients, DNA methylation does not seem to contribute to respiratory muscle dysfunction in COPD patients, despite its potential contribution to muscle development and myogenesis.

The transcription factors myocyte enhancer factor (MEF)2 and Yin Yang (YY)1 seem to play a relevant role in muscle development, metabolic adaptation, and in the determination of muscle fiber type [43]. Interestingly, in the current study, no differences in MEF2D and YY1 were observed in the diaphragms between COPD patients and control subjects, while a significant

### Table 4. Fiber type composition in diaphragm muscles of all the study subjects.

| Muscle fiber type composition | Controls N = 10 | Mild, moderate and severe COPD N = 18 |
|-----------------------------|----------------|----------------------------------------|
| Type I fibers, percentages  | 48 (5)         | 52 (7)                                 |
| Type II fibers, percentages | 52 (5)         | 48 (7)                                 |
| Type I fibers, CSA (μm²)    | 2407 (782)     | 2483 (716)                             |
| Type II fibers, CSA (μm²)   | 2641 (713)     | 2410 (983)                             |

Values are expressed as mean (standard deviation).

Abbreviations: CSA, cross-sectional area, μm, micrometer.

doi:10.1371/journal.pone.0111514.t004

Figure 9. Epigenetic profile in the diaphragm of mild-to-moderate COPD patients. The main results encountered in the study are briefly depicted in the figure. Arrows express significant differences in COPD patients compared to controls. Main findings were that HDAC4 and MEF2C protein levels were increased, whereas miR-1, miR-133, and miR-206 were decreased in COPD patients compared to controls. Abbreviations: COPD, chronic obstructive pulmonary disease; HDACs, histone deacetylases; silent mating type information regulation 2 homolog (SIRT)-1, silent information regulator 1; miR, microRNA; TFs, transcription factors; MEF, myocyte-enhancer factor; YY1, yin yang 1; SRF, serum response factor; and BAF, BRG1-associated factors.

doi:10.1371/journal.pone.0111514.g009
rise in MEF2C was, indeed, seen in the patients. It is likely that in COPD, the adaptive potential is still preserved in the main respiratory muscle, at least through MEF2C upregulation.

Accumulation of SUMO ligases was shown to be associated with premature senescence of primary myogenic cultured cells [44], and other cell models [45-46]. In this model, atrophy and muscle wasting could be partly the result of the premature senescence of satellite cells, which ultimately would lead to decreased growth and repair potential. As such, premature satellite cell senescence through SUMO ligases among other mechanisms underlies the pathophysiology of muscular dystrophies [18]. In the present investigation, expression levels of SUMO-2 and -3 did not differ between groups in the diaphragm muscle, thus suggesting that premature senescence may not be a relevant mechanism of respiratory muscle dysfunction in COPD, at least in patients with mild-to-moderate airflow limitation.

Study limitations

Diaphragm muscle biopsies from the study subjects were obtained during thoracotomy because of localized lung lesions, the gold standard technique to obtain diaphragm specimens from different populations. Although lung volume reduction surgery also makes it possible to obtain diaphragm specimens, only very severe COPD patients undergo that type of surgery, thus, making the study of mild-to-moderate patients or control subjects impossible. Therefore, diagnostic-therapeutic thoracotomy is the only approach available for studying moderate and mild COPD and normal lung function subjects. Accordingly, subjects recruited for the purpose of the study shares a common morbidity; the presence of a small and localized lung neoplasm. Nevertheless, we do not believe that this condition has made any significant contribution to the results obtained in the analyses of the diaphragm muscles, since extremely restrictive criteria were employed to properly select the population, and subjects showing either nutritional abnormalities, signs of chronic inflammation, or paraneoplastic syndromes, were systematically excluded. Therefore, we consider all the findings reported in the study to be rather associated with COPD.

Conclusions

In the main respiratory muscle of COPD patients with a wide range of disease severity and normal body composition, muscle-specific microRNAs were downregulated, while HDAC4 and MEF2C levels were upregulated. It is likely that these epigenetic events act as biological adaptive mechanisms to better overcome the continuous inspiratory loads imposed to the respiratory system in COPD. These findings may offer novel therapeutic strategies to specifically target respiratory muscle dysfunction in patients with COPD.

Supporting Information

File S1 Detailed methodologies. Figure S1 in file S1: Representative immunoblots of vinculin protein content (117 kDa) as the loading control in the diaphragms. In each fresh mini-gel, first lane from left corresponds to the molecular weight marker. All gels were always run together within the same minigel electrophoresis box. Definition of abbreviations: KDa, kilodaltons. Figure S2 in file S1: Representative immunohistochemical preparations corresponding to the staining of type II fibers in the diaphragms of a healthy control subject and a patient with severe COPD. (DOC)

Acknowledgments

The authors are grateful to Ms. Mireia Achinellò and Dr. Sergio Pascual-Guardia for their help with patient reports and information, and Mr. Francisco Sánchez and Dr. Carme Casadevall for their contribution to muscle structure and microRNA expression analyses.

Author Contributions

Conception and design: EB JG. Patient assessment and recruitment and sample collection: RA JML. Molecular biology analyses: EPV EB. Statistical analyses, data interpretation and presentation: EPV EB. Wrote the paper: EPV. Manuscript drafting and intellectual input: EB JG EPV.

References

1. Gayan-Ramirez G, Decramer M (2013) Mechanisms of striated muscle dysfunction during acute exacerbations of COPD. J Appl Physiol 114: 1291–1299. doi: 10.1152/japplphysiol.00472.2012.
2. Gosselink R, Troosters T, Decramer M (1996) Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 153: 976–980.
3. Gea J, Agusti A, Roca J (2013) Pathophysiology of muscle dysfunction in COPD. J Appl Physiol 114: 1222–1234. doi: 10.1152/japplphysiol.00891.2012.
4. Vilaro J, Ramirez-Sarmiento A, Martinez-Llorens JM, Mendez T, Alvarez M, et al. (2010) Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med 104: 1906–1909. doi: 10.1016/j.rmed.2010.05.001.
5. Simlowski T, Yau S, Gauthier AP, Macklem PT, Bellerme F (1991) Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med 325: 917–925. doi: 10.1056/NEJM199109263251304.
6. Mantilla CB, Sierck GC (2013) Neuronotor control in chronic obstructive pulmonary disease. J Appl Physiol 114: 1246–1252. doi: 10.1152/japplphysiol.01212.2012.
7. Levine S, Bashir MH, Clanton TL, Powers SK, Singhal S (2013) COPD elicits remodeling of the diaphragm and vastus lateralis muscles in humans. J Appl Physiol 114: 1246–1252. doi: 10.1152/japplphysiol.01212.2012.
8. Remels AH, Gosker HR, Langen RC, Schols AM (2002) The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol 114: 1253–1262. doi: 10.1152/japplphysiol.00790.2012.
9. Ortega F, Toral J, Cejudo P, Villagomez R, Sanchez H, et al. (2002) Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166: 699–704. doi: 10.1164/rccm.200110-20107R.
10. Donaldson A, Natanak SA, Lewis A, Man WD, Hopkinson NS, et al. (2013) Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax 68: 1140–1149. doi: 10.1136/thoraxjnl-2012-203129.
11. Lewis A, Riddoch-Contreras J, Natanak SA, Donaldson A, Man WD, et al. (2012) Downregulation of the serum response factor/mr1-axis in the quadriceps of patients with COPD. Thorax 67: 26–34. doi: 10.1136/thoraxjnl-2011-200309.
12. Puig-Villanova E, Austin P, Martinez-Llorens J, Gea J, Barreiro E (2014) Do-epigenetic events take place in the vastus lateralis of patients with mild chronic obstructive pulmonary disease? PLoS One 9: e102296. doi: 10.1371/journal.pone.0102296.
13. Allen DL, Bandura ER, Harrison BC, Thurug S, Stodiek LS, et al. (2009) Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol 106: 592–595. doi: 10.1152/japplphysiol.00780.2009.
14. McCarthy JJ, Eser KA, Peterson CA, Dupont-Versteegden EE (2009) Evidence of MyoMIR network regulation of beta-myosin heavy chain gene expression during skeletal muscle atrophy. J Physiol Genomics 39: 219–226. doi: 10.1152/physiogenomics.00042.2009.
15. McCarthy JJ, Eser KA (2007) MicroRNA-1 and microRNA-153a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 102: 306–313. doi: 10.1152/japplphysiol.00926.2006.
16. Alamdari N, Smith JJ, Avezza Z, Hasselgren PO (2010) Sepsis and glucocorticoids upregulate p500 and downregulate HDAC6 expression and activity in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 299: R509–R520. doi: 10.1152/ajpregu.00358.2009.
17. Seigneurin-Berry D, Verdel A, Curat S, Lemercier C, Garin J, et al. (2001) Identification of components of the murine heart deacteystyke 6 complex: Link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 21: 8035–8044. doi: 10.1128/MCB.21.23.8035-8044.2001.
18. Kudryashova E, Kramerova I, Spencer MJ (2012) Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H. J Clin Invest 122: 1764–1776. doi: 10.1172/JCI59581.
19. Miravitles M, Solé-Cataluna JJ, Calle M, Molina J, Alamago P, et al. (2012) Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable
Epigenetic Regulation in Diaphragms of COPD

COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 48: 247–257. doi: 10.1016/j.arbres.2012.04.001.

20. Miravilles M, Calle M, Soler-Cataluna JJ (2012) Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol 48: 86–90. doi: 10.1016/j.arbres.2011.10.007.

21. Miravilles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, et al. (2014) Spanish Guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 50 Suppl 1: 1–16. doi: 10.1016/S0300-2894(14)70070-5.

22. Ferronello C, Rabiniwitz R, Ausin P, Poit-Vilainova E, Corazza C, et al. (2012) Does oxidative stress mediate limb muscle atrophy in severe COPD patients? Eur Respir J 40: 851–862. doi: 10.1183/09031936.00137211.

23. Marin-Corral J, Minguela J, Ramirez-Sarmiento AL, Hussain SN, Gea J, et al. (2009) Oxidized proteins and superoxide anion production in the diaphragm of severe COPD patients. Eur Respir J 33: 1309–1319.

24. Andreu AL, Martinez R, Marti R, Garcia-Arumi E (2009) Quantification of mitochondrial DNA copy number: pre-analytical factors. Mitochondrion 9: 242–246. doi: 10.1016/j.mito.2009.02.006.

25. Hadoux J, Favier J, Sossay JY, Leboulleux S, Al GA, et al. (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. doi: 10.1002/ijc.28913.

26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. doi: 10.1006/meth.2001.1262.

27. Barreiro E, de la Puente B, Minguella J, Corominas JM, Serrano S, et al. (2005) Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 1116–1124. doi: 10.1164/rccm.200407-887OC.

28. Op den Kamp CM, Langen RC, Minnaard R, Kelders MC, Snepvangers FJ, et al. (2012) Pre-cachexia in patients with stages I-III non-small cell lung cancer: a randomized controlled trial. Thorax 67: 350–357. doi: 10.1136/thoraxjnl-2011-201122.

29. Toth MJ, Miller MS, Callahan DM, Sweeny AP, Nunez I, et al. (2013) Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics. J Appl Physiol 114: 858–868. doi: 10.1152/japplphysiol.01474.2012.

30. Levine S, Kaiser L, Leferovich J, Tikunov B (1997) Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 337: 1799–1806. doi: 10.1056/NEJM199712183372503.

31. Polkey MI, Kyroussis D, Hambegard GH, Mills GH, Green M, et al. (1996) Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154: 1310–1317. doi: 10.1164/ajrccm.154.5.8912741.

32. Barreiro E, Sznajder JJ (2013) Epigenetic regulation of muscle phenotype and adaptation: a potential role in COPD muscle dysfunction. J Appl Physiol 114: 1263–1272. doi: 10.1152/japplphysiol.01027.2012.

33. Perdiguero E, Sossa-Victor P, Ballestar E, Munoz-Canoves P (2009) Epigenetic regulation of myogenesis. Epigenetics 4: 541–550.

34. Nakajima N, Takahashi T, Kitamura R, Iodono K, Aida S, et al. (2006) MicroRNA-1 facilitates skeletal myogenic differentiation without affecting osteoblastic and adipogenic differentiation. Biochem Biophys Res Commun 340: 1006–1012. doi: 10.1016/j.bbrc.2006.09.153.

35. Liu N, Williams AH, Mecarmin JM, Becprozvanysa S, Shelton J, et al. (2012) microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J Clin Invest 122: 2034–2043. doi: 10.1172/JCI61263.

36. Orezco-Levi M, Lloreta J, Minguela J, Serrano S, Broquetas J, et al. (2001) Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 1744–1749.

37. Alandari N, Aversa Z, Castelli E, Hasselgren PO (2013) Acetylation and deacetylation processes and effects on cellular function. Mol Cell. doi: 10.1016/j.molcel.2012.05.019.

38. Sadoul K, Boyault C, Pabon M, Khochbin S (2008) Regulation of protein turnover by acetylation and deacetylation. Biochimie 90: 306–312. doi: 10.1016/j.biochi.2007.06.009.

39. Ito K, Ito M, Elliott WM, Costo B, Caramori G, et al. (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352: 1967–1976. doi: 10.1056/NEJMoa041892.

40. Mizuno S, Yasuo M, Bogard HJ, Kraskausas D, Natajara R, et al. (2011) Inhibition of histone deacetylase causes emphysema. Am J Physiol Lung Cell Mol Physiol 300: L402–L413. doi: 10.1152/ajplung.00257.2010.

41. Chen LF, Greene WC (2003) Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Biol (Berl) 31: 549–557. doi: 10.1007/s00105-003-0469-0.

42. Saccone V, Comalfi S, Giordani L, Mozzetta C, Barozzi I, et al. (2014) HDAC-regulated myosinRs control RARf0 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes Dev 28: 841–857. doi: 10.1101/gad.234860.113.

43. Potthoff MJ, Wu H, Arnold MA, Shelton JM, Backs J, et al. (2007) Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest 117: 2459–2467. doi: 10.1172/JCI31960.

44. Andreou AM, Tavernarakis N (2009) SUMOylation and cell signalling. Trends Cell Biol 19: 474–482. doi: 10.1016/j.tcb.2009.02.019.

45. Bischof O, Schwamborn K, Martin N, Werner A, Sustmann C, et al. (2006) The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 22: 785–794. doi: 10.1016/j.molcel.2006.05.016.

46. Bischof O, Dejean A (2007) SUMO is growing senescent. Cell Cycle 6: 677–681.